Boehringer Ingelheim has taken an option on a family of GPR52 agonist compounds with potential in schizophrenia from Sosei Heptares, in a €755m deal.

Shares in Neurocrine Bioscience took a tumble after the company reported mid-stage data for a key pipeline drug for schizophrenia that failed to impress investors. The 19% after-market selloff ...

Schizophrenia exhibits significant variability in brain structures, traditionally viewed as static due to heterogeneous subgroups. Here the authors use magnetic resonance imaging data from 1,792 ...